A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : RLAI / risperidone long-acting injection

[Related PubMed/MEDLINE]
Total Number of Papers: 120
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   RLAI  (>> Co-occurring Abbreviation)
Long Form:   risperidone long-acting injection
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 Modeling the Choice Between Risperidone Long-Acting Injectable and Generic Risperidone from the Perspective of a Japanese Hospital. ---
2019 Switching patients with schizophrenia from paliperidone palmitate to aripiprazole lauroxil: A 6-month, prospective, open-label study. AL, PP
2018 Comparison of Paliperidone Palmitate and Risperidone Long-Acting Injection in Schizophrenic Patients: Results From a Multicenter Retrospective Cohort Study in France. PP
2018 Efficacy and Safety Profile of Risperidone Long-acting Injection in Adolescents in a Real-life Setting. CGI-S
2017 Bipolar patients treated with long-acting injectable risperidone in Taiwan: A 1-year mirror-image study using a national claims database. BD, ER
2017 Does Risperidone Long Acting Injectable Depot (RLAI) Reduce number of Admissions to Hospital. ---
2016 An Exploratory, Open-Label, Randomized Trial Comparing Risperidone Long-Acting Injectable with Oral Antipsychotic Medication in the Treatment of Early Psychosis. CGI-S, PANSS, RCT, SS
2016 Cross-sectional comparison of first-generation antipsychotic long-acting injections vs risperidone long-acting injection: patient-rated attitudes, satisfaction and tolerability. FGA-LAI, LUNSERS, SWAM
2016 Effectiveness of long-acting antipsychotics in clinical practice : 1. A retrospective, 18-month follow up and comparison between paliperidone palmitate, risperidone long-acting injection and zuclopenthixol decanoate. CGI, LAIs
10  2016 Effectiveness of long-acting antipsychotics in clinical practice: 2. Effects of antipsychotic polypharmacy on risperidone long-acting injection and zuclopenthixol decanoate. APP, CGI, LAIs
11  2016 Effects of Discontinuation of Paliperidone Long-Acting Injectable After Switching from Risperidone Long-Acting Injectable Switching. CP, PP
12  2016 Remission and employment status in schizophrenia and other psychoses: One-year prospective study in Croatian patients treated with risperidone long acting injection. CGI-S, PANSS
13  2016 Risperidone long-acting injectable in the treatment of treatment-resistant schizophrenia with dopamine supersensitivity psychosis: Results of a 2-year prospective study, including an additional 1-year follow-up. BPRS, DSP, TRS
14  2016 The Comparative Effects of Risperidone Long-Acting Injection and Paliperidone Palmitate on Social Functioning in Schizophrenia: A 6-Month, Open-Label, Randomized Controlled Pilot Trial. DIEPSS, PANSS, PP, SECT, SFS, UPSA-B
15  2015 A comparison of the effectiveness of risperidone, haloperidol and flupentixol long-acting injections in patients with schizophrenia--A nationwide study. BZD, FGA, SGA
16  2015 Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK. AOM 400, ICER, LAI, MTCs, NHS, OLAI, PLAI, PSS
17  2015 Effectiveness, Good Tolerability, and High Compliance of Doses of Risperidone Long-Acting Injectable Higher Than 75 mg in People With Severe Schizophrenia: A 3-Year Follow-Up. CAN, CGI-S
18  2015 Five-year patient outcomes with risperidone long-acting injection or oral aripiprazole. ---
19  2015 Risperidone long-acting injection and 1-year rehospitalization rate of schizophrenia patients: A retrospective cohort study. ---
20  2015 Switching from risperidone long-acting injectable to paliperidone long-acting injectable or oral antipsychotics: analysis of a Medicaid claims database. APs, PP
21  2014 A prospective comparative study of risperidone long-acting injectable for treatment-resistant schizophrenia with dopamine supersensitivity psychosis. BPRS, CGI-S, DSP, ESRS, GAF, TRS
22  2014 A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea. AEs, ITT, PANSS, PP
23  2014 Design and validation of standardized clinical and functional remission criteria in schizophrenia. ICD10, IRC, MINI, PSP, SCFRC
24  2014 Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain - a cost-effectiveness comparison. DES, LYs, OLAI, QALYs
25  2014 Paliperidone palmitate versus oral risperidone and risperidone long-acting injection in patients with recently diagnosed schizophrenia: a tolerability and efficacy comparison. AEs, PP
26  2014 Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens. AE, PANSS, PP
27  2014 Risperidone long-acting injection in the treatment of schizophrenia: 24-month results from the electronic Schizophrenia Treatment Adherence Registry in Canada. CGI-S, e-STAR, GAF, PSP, vs
28  2013 Comparison of treatment response in second-episode versus first-episode schizophrenia. ---
29  2013 Cost analysis of risperidone long-acting injection in the treatment of schizophrenia and schizoaffective disorders in Hong Kong: an approach using generalised estimating equations. CI
30  2013 Cost effectiveness of paliperidone palmitate for the treatment of schizophrenia in Germany. OLAI, PLAI, PSA, QALYs
31  2013 Effect of the addition of aripiprazole on hyperprolactinemia associated with risperidone long-acting injection. ---
32  2013 Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case-control study. CI
33  2013 Functional recovery results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE). QOL, SF-12, SOFAS, SQLS-R4
34  2013 Identification of clinically meaningful relationships among cognition, functionality, and symptoms in subjects with schizophrenia or schizoaffective disorder. NCS, PANSS, PSP
35  2013 Long-term remission in schizophrenia and schizoaffective disorder: results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE). SD
36  2013 Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics. PANSS
37  2013 Pharmacogenetic study on risperidone long-acting injection: influence of cytochrome P450 2D6 and pregnane X receptor on risperidone exposure and drug-induced side-effects. CYP2D6, RIS
38  2013 Risperidone long-acting injection in Schizophrenia Spectrum Illnesses compared to first generation depot antipsychotics in an outpatient setting in Canada. EPS, FGAI
39  2013 Six-month open-label follow-up of risperidone long-acting injection use in pediatric bipolar disorder. CGAS, CGAS, CGI
40  2012 A cost-consequence analysis of long-acting injectable risperidone in schizophrenia: a one-year mirror-image study with national claim-based database in Taiwan. ---
41  2012 A review of paliperidone palmitate. PLAI
42  2012 A study of the efficacy and safety of switching from oral risperidone to risperidone long-acting injection in older patients with schizophrenia. DIEPSS
43  2012 Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden. eq, OLAI, QALY
44  2012 Descriptive analyses of the aripiprazole arm in the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE). AEs
45  2012 Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the Cohort for the General study of Schizophrenia (CGS). CGS
46  2012 Hospitalisation Utilisation and Costs in Schizophrenia Patients in Finland before and after Initiation of Risperidone Long-Acting Injection. ---
47  2012 Long acting risperidone in Australian patients with chronic schizophrenia: 24-month data from the e-STAR database. e-STAR
48  2012 One-year treatment continuation in patients prescribed risperidone long-acting injection in New Zealand: a retrospective study. ---
49  2012 Patients' acceptance of the deltoid application of risperidone long-acting injection. ---
50  2012 Risperidone and total 9-hydroxyrisperidone in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 2002-2010. ---
51  2012 Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable. CGI-S, GAF, PANSS, TEAEs
52  2012 The cost-effectiveness of risperidone long-acting injection in the treatment of schizophrenia. ---
53  2012 The influence of switching from haloperidol decanoate depot to risperidone long-acting injection on the clinical symptoms and cognitive function in schizophrenia. ---
54  2012 The influence of switching from oral risperidone to risperidone long-acting injection on the clinical symptoms and cognitive function in schizophrenia. PANSS, STM-COMET
55  2012 Treatment adherence with early prescription of long-acting injectable antipsychotics in recent-onset schizophrenia. CGI, GAF, LAIAs
56  2012 Using ultrasonography in evaluating the intramuscular injection techniques used for administering drug treatments to schizophrenic patients in Japan. IM, TDI
57  2011 Adjunctive long-acting risperidone in patients with bipolar disorder who relapse frequently and have active mood symptoms. CGI-BP-S, MADRS, YMRS
58  2011 Determining what practising clinicians believe about long-acting injectable antipsychotic medication. LAI
59  2011 Emotion processing in schizophrenia: fMRI study of patients treated with risperidone long-acting injections or conventional depot medication. CONV, HC, vmPFC
60  2011 Explicit review of risperidone long-acting injection prescribing practice. LAI
61  2011 Long-term efficacy of risperidone long-acting injectable in bipolar disorder with psychotic features: a prospective study of 3-year outcomes. BD
62  2011 [Case of schizophrenia in which depressive and negative symptoms relapsed on switching from oral risperidone to risperidone long-acting injection]. ---
63  2010 A Pilot, 15-month, randomised effectiveness trial of Risperidone long-acting injection (RLAI) versus oral atypical antipsychotic agents (AAP) in persons with bipolar disorder. AAP, BPD, RLAIs
64  2010 Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America. CGI-S, GAF, PSP
65  2010 Correlates, change and 'state or trait' properties of insight in schizophrenia. ---
66  2010 Cost effectiveness of long-acting risperidone in Sweden. DES, PANSS, PSA, WTP
67  2010 Diffusion of a new drug: a comparative analysis of adoption, treatment complexity, and persistence of risperidone long-acting injectable therapy in the Netherlands. FGA
68  2010 Does oral antipsychotic pre-treatment influence outcome of a switch to long-acting injectable risperidone in patients with schizophrenia? OQAZ, RIS
69  2010 Emerging treatments in the management of bipolar disorder - focus on risperidone long acting injection. FDA
70  2010 Establishing remission and good clinical functioning in schizophrenia: predictors of best outcome with long-term risperidone long-acting injectable treatment. PANSS, StoRMi
71  2010 Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review. OP
72  2010 Long-term observation of patients successfully switched to risperidone long-acting injectable: A retrospective, naturalistic 18-month mirror-image study of hospitalization rates and therapy costs. ---
73  2010 Patient perspectives on use of long-acting antipsychotics in bipolar disorder: focus on risperidone injection. ---
74  2010 Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial. AEs, ESRS
75  2010 Risperidone long-acting injection (RLAI): the 12-week efficacy and tolerability in Thai patients with chronic schizophrenia. BW, MPS, YESS
76  2010 Risperidone long-acting injection: factors associated with changes in bed stay and hospitalisation in a 3-year naturalistic follow-up. ---
77  2010 Safety and efficacy of long-acting injectable risperidone in daily practice: an open-label, noninterventional, prospective study in schizophrenia and related disorders. AE
78  2010 Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: efficacy, quality of life and functional outcome. HRQoL, PANSS
79  2010 Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: reasons for switching and safety. AEs
80  2010 The combined use of risperidone long-acting injection and clozapine in patients with schizophrenia non-adherent to clozapine: a case series. ---
81  2010 Treatment effectiveness and adherence in patients with schizophrenia treated with risperidone long-acting injection. ---
82  2010 Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries. e-STAR, GAF
83  2009 A descriptive, open-label, long-term follow-up survey of psychotic patients receiving risperidone long-acting injectable: Preliminary results. CGI-S, GAF
84  2009 A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome. AAT, AAT, ITT, ORAL, ROMI
85  2009 Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry. CGI-S, e-STAR, GAF
86  2009 Dosing patterns in Europe: Efficacy and safety of risperidone long-acting injectable in doses of 25, 37.5 and 50 mg. AEs, CGI-S, OR, PANSS, StoRMi
87  2009 Experience with injectable long-acting risperidone in long-term therapy after an acute episode of schizophrenia: the SPHERE Study. ---
88  2009 Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). AP, e-STAR
89  2009 Relapse and long-acting injectable risperidone: a 1-year mirror image study with a national claims database in Taiwan. ---
90  2009 Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder. AEs, CGI, DAI30, GAF, PANSS
91  2009 Risperidone long acting injection: Findings of a 2-year retrospective follow-up study. ---
92  2009 Risperidone long-acting injection: a 6-year mirror-image study of healthcare resource use. ---
93  2009 Risperidone long-acting injection: a prospective 3-year analysis of its use in clinical practice. ---
94  2008 Effectiveness of risperidone long-acting injection in first-episode schizophrenia: in naturalistic setting. ---
95  2008 Impact of risperidone long acting injection on resource utilization in psychiatric secondary care. ---
96  2008 Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: a preliminary study. ---
97  2008 Long-acting risperidone improves negative symptoms in stable psychotic patients. PANSS
98  2008 Long-term remission in schizophrenia and related psychoses with long-acting risperidone: results obtained in an open-label study with an observation period of 18 months. AEs, StoRMi
99  2008 Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies. BMI, ESRS, PANSS
100  2008 Predictors for starting depot administration of risperidone in chronic users of antipsychotics. FGAs